Inra spinout Nextbiotix has attracted capital from the institute itself as well as Biocodex and other institutional investors.
Nextbiotix, a France-based biopharmaceutical spinout from Inra, has raised €7m ($8.2m) in series A funding from investors including the agricultural research institute itself.
Auriga Partners led the round, while pharmaceutical company Biocodex and Cap Innov’Est, a regional investment vehicle managed by French state-owned investment bank Bpifrance, and private equity firm Sofimac Innovation also took part.
Founded in 2016, Nextbiotix is working on microbiome-based treatments for major inflammatory bowel diseases. The spinout’s approach relies on single microbial strains that interact with…
